← Back to patent-cliff list
CAS 148256-46-6
(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-oxirane]
Codes: GANA-002
Application context (from source-drug indications)
CDKL5缺乏症GanaxoloneSeizureGanaxolone癫痫综合征Ganaxolone婴儿痉挛GanaxoloneEpilepsyGanaxoloneTuberous sclerosisGanaxolone
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ganaxolone | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)hexadecahydro-3H-cyclopenta[a]phenanthren-3-one→(3R,5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-17-(2-methyl-1,3-dioxolan-2-yl)hexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-oxirane]→(3R,5S,8R,9S,10S,13S,14S,17S)-3,10,13-trimethyl-17-(2-methyl-1,3-dioxolan-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-ol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.